{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:54:30Z","timestamp":1787842470380,"version":"build-2784847793"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40256-022-00537-6","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T02:06:10Z","timestamp":1652666770000},"page":"657-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis"],"prefix":"10.1007","volume":"22","author":[{"given":"Mingming","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuojing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daxin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0031-8102","authenticated-orcid":false,"given":"Xiaoxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"537_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0140-6736(19)32007-0","volume":"395","author":"GR Dagenais","year":"2020","unstructured":"Dagenais GR, Leong DP, Rangarajan S, et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet. 2020;395:785\u201394.","journal-title":"Lancet"},{"key":"537_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41569-018-0119-4","volume":"16","author":"D Zhao","year":"2019","unstructured":"Zhao D, Liu J, Wang M, et al. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16:203\u201312.","journal-title":"Nat Rev Cardiol"},{"key":"537_CR3","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;140:e596\u2013646.","journal-title":"Circulation"},{"key":"537_CR4","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","volume":"384","author":"WS Jones","year":"2021","unstructured":"Jones WS, Mulder H, Wruck LM, et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med. 2021;384:1981\u201390.","journal-title":"N Engl J Med"},{"key":"537_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71\u201386.","journal-title":"BMJ"},{"key":"537_CR6","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","volume":"392","author":"JM Gaziano","year":"2018","unstructured":"Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392:1036\u201346.","journal-title":"Lancet"},{"key":"537_CR7","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"L Bowman","year":"2018","unstructured":"Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529\u201339.","journal-title":"N Engl J Med"},{"key":"537_CR8","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","volume":"379","author":"JJ Mcneil","year":"2018","unstructured":"Mcneil JJ, Nelson MR, Woods RL, et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med. 2018;379:1519\u201328.","journal-title":"N Engl J Med"},{"key":"537_CR9","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","volume":"379","author":"JJ Mcneil","year":"2018","unstructured":"Mcneil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379:1509\u201318.","journal-title":"N Engl J Med"},{"key":"537_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jama.2018.20578","volume":"321","author":"SL Zheng","year":"2019","unstructured":"Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events a systematic review and meta-analysis. JAMA. 2019;321:277\u201387.","journal-title":"JAMA"},{"key":"537_CR11","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2147\/TCRM.S198403","volume":"15","author":"W Xie","year":"2019","unstructured":"Xie W, Luo Y, Liang X, et al. The efficacy and safety of aspirin as the primary prevention of cardiovascular disease: an updated meta-analysis. Ther Clin Risk Manag. 2019;15:1129\u201340.","journal-title":"Ther Clin Risk Manag"},{"key":"537_CR12","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.amjmed.2019.05.015","volume":"132","author":"R Shah","year":"2019","unstructured":"Shah R, Khan B, Latham SB, et al. A meta-analysis of aspirin for the primary prevention of cardiovascular diseases in the context of contemporary preventive strategies. Am J Med. 2019;132:1295-1304.e3.","journal-title":"Am J Med"},{"key":"537_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3390\/jcm8050609","volume":"8","author":"M-H Lin","year":"2019","unstructured":"Lin M-H, Lee C-H, Lin C, et al. Low-dose aspirin for the primary prevention of cardiovascular disease in diabetic individuals: a meta-analysis of randomized control trials and trial sequential analysis. J Clin Med. 2019;8:609.","journal-title":"J Clin Med"},{"key":"537_CR14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12916-019-1428-0","volume":"17","author":"G Gelbenegger","year":"2019","unstructured":"Gelbenegger G, Postula M, Pecen L, et al. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. BMC Med. 2019;17:198.","journal-title":"BMC Med"},{"key":"537_CR15","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.amjmed.2020.04.028","volume":"133","author":"M Nudy","year":"2020","unstructured":"Nudy M, Cooper J, Ghahramani M, et al. Aspirin for primary atherosclerotic cardiovascular disease prevention as baseline risk increases a meta-regression analysis. Am J Med. 2020;133:1056\u201364.","journal-title":"Am J Med"},{"key":"537_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a1840","volume":"337","author":"J Belch","year":"2008","unstructured":"Belch J, Maccuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337: a1840.","journal-title":"BMJ"},{"key":"537_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jama.2010.221","volume":"303","author":"FG Fowkes","year":"2010","unstructured":"Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841\u20138.","journal-title":"JAMA"},{"key":"537_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102391","volume":"16","author":"W Masson","year":"2022","unstructured":"Masson W, Barbagelata L, Lavalle-Cobo A, et al. Low-doses aspirin in the primary prevention of cardiovascular disease in patients with diabetes: meta-analysis stratified by baseline cardiovascular risk. Diabetes Metab Syndr. 2022;16: 102391.","journal-title":"Diabetes Metab Syndr"},{"key":"537_CR19","first-page":"293","volume":"90","author":"G Masson","year":"2020","unstructured":"Masson G, Lobo M, Masson W, et al. Aspirin in primary prevention. Meta-analysis stratified by baseline cardiovascular risk. Arch Cardiol Mex. 2020;90:293\u20139.","journal-title":"Arch Cardiol Mex"},{"key":"537_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.592116","volume":"11","author":"B Zhao","year":"2020","unstructured":"Zhao B, Wu Q, Wang L, et al. Pros and cons of aspirin for the primary prevention of cardiovascular events: a secondary study of trial sequential analysis. Front Pharmacol. 2020;11: 592116.","journal-title":"Front Pharmacol"},{"key":"537_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1056\/NEJMoa2028220","volume":"384","author":"S Yusuf","year":"2021","unstructured":"Yusuf S, Joseph P, Dans A, et al. Polypill with or without aspirin in persons without cardiovascular disease. N Engl J Med. 2021;384:216\u201328.","journal-title":"N Engl J Med"},{"key":"537_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339: b2700.","journal-title":"BMJ"},{"key":"537_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"537_CR24","doi-asserted-by":"publisher","first-page":"804","DOI":"10.7326\/M15-2113","volume":"164","author":"JM Guirguis-Blake","year":"2016","unstructured":"Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the us preventive services task force. Ann Intern Med. 2016;164:804\u201313.","journal-title":"Ann Intern Med"},{"key":"537_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/eurheartj\/ehy813","volume":"40","author":"AN Mahmoud","year":"2019","unstructured":"Mahmoud AN, Gad MM, Elgendy AY, et al. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J. 2019;40:607\u201317.","journal-title":"Eur Heart J"},{"key":"537_CR26","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J. 2016;37:2315\u201381.","journal-title":"Eur Heart J"},{"key":"537_CR27","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227\u2013337.","journal-title":"Eur Heart J"},{"key":"537_CR28","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/jrsm.1104","volume":"5","author":"E Kulinskaya","year":"2014","unstructured":"Kulinskaya E, Wood J. Trial sequential methods for meta-analysis. Res Synth Methods. 2014;5:212\u201320.","journal-title":"Res Synth Methods."},{"key":"537_CR29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","volume":"61","author":"J Brok","year":"2008","unstructured":"Brok J, Thorlund K, Gluud C, et al. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol. 2008;61:763\u20139.","journal-title":"J Clin Epidemiol"},{"key":"537_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","volume":"17","author":"J Wetterslev","year":"2017","unstructured":"Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. 2017;17:39.","journal-title":"BMC Med Res Methodol"},{"key":"537_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","volume":"61","author":"J Wetterslev","year":"2008","unstructured":"Wetterslev J, Thorlund K, Brok J, et al. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61:64\u201375.","journal-title":"J Clin Epidemiol"},{"key":"537_CR32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.17085\/apm.21038","volume":"16","author":"H Kang","year":"2021","unstructured":"Kang H. Trial sequential analysis: novel approach for meta-analysis. Anesth Pain Med. 2021;16:138\u201350.","journal-title":"Anesth Pain Med"},{"key":"537_CR33","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1161\/CIRCULATIONAHA.116.025760","volume":"135","author":"Y Saito","year":"2017","unstructured":"Saito Y, Okada S, Ogawa H, et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial. Circulation. 2017;135:659\u201370.","journal-title":"Circulation"},{"key":"537_CR34","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1001\/jama.2014.15690","volume":"312","author":"Y Ikeda","year":"2014","unstructured":"Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312:2510\u201320.","journal-title":"JAMA"},{"key":"537_CR35","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa050613","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293\u2013304.","journal-title":"N Engl J Med"},{"key":"537_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","volume":"357","author":"MC Roncaglioni","year":"2001","unstructured":"Roncaglioni MC. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001;357:89\u201395.","journal-title":"Lancet"},{"key":"537_CR37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","volume":"351","author":"TW Meade","year":"1998","unstructured":"Meade TW, Wilkes HC, Kelleher CC, et al. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351:233\u201341.","journal-title":"Lancet"},{"key":"537_CR38","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755\u201362.","journal-title":"Lancet"},{"key":"537_CR39","first-page":"1000","volume":"48","author":"Chinese Society of Cardiology of Chinese Medical Association","year":"2020","unstructured":"Chinese Society of Cardiology of Chinese Medical Association, et al. Chinese guideline on the primary prevention of cardiovascular diseases [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:1000\u201338.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"537_CR40","unstructured":"Anonymous. Aspirin use to prevent cardiovascular disease: preventive medication. Available at: www.uspreventiveservicestaskforce.org\/uspstf\/draft-recommendation\/aspirin-use-to-prevent-cardiovascular-disease-preventive-medication#fullrecommendationstart.;375"},{"key":"537_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2521","volume":"375","author":"E Mahase","year":"2021","unstructured":"Mahase E. US taskforce advises against low dose aspirin for primary prevention of cardiovascular disease. BMJ. 2021;375: n2521.","journal-title":"BMJ"},{"key":"537_CR42","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.2337\/dc22-S010","volume":"45","author":"B Draznin","year":"2022","unstructured":"Draznin B, Aroda VR, Bakris G, et al. 10. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142022. Diabetes Care. 2022;45:S144-s174.","journal-title":"Diabetes Care"},{"key":"537_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.720113","volume":"8","author":"Y Chen","year":"2021","unstructured":"Chen Y, Yin C, Li Q, et al. Misuse of aspirin and associated factors for the primary prevention of cardiovascular disease. Front Cardiovasc Med. 2021;8: 720113.","journal-title":"Front Cardiovasc Med."},{"key":"537_CR44","doi-asserted-by":"publisher","first-page":"13603","DOI":"10.1038\/s41598-021-93179-8","volume":"11","author":"MB Christensen","year":"2021","unstructured":"Christensen MB, Jimenez-Solem E, Ernst MT, et al. Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998\u20132018. Sci Rep. 2021;11:13603.","journal-title":"Sci Rep"},{"issue":"3","key":"537_CR45","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.121.007979","volume":"15","author":"RS Hira","year":"2022","unstructured":"Hira RS, Gosch KL. Potential impact of the 2019 ACC\/AHA guidelines on the primary prevention of cardiovascular disease recommendations on the inappropriate routine use of aspirin and aspirin use without a recommended indication for primary prevention of cardiovascular disease in cardiology practices: insights from the NCDR PINNACLE Registry. Circ Cardiovasc Qual Outcomes. 2022;15(3): e007979.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"4","key":"537_CR46","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1177\/2047487320908698","volume":"28","author":"K Kotseva","year":"2021","unstructured":"Kotseva K, De Backer G, De Bacquer D, et al. Primary prevention efforts are poorly developed in people at high cardiovascular risk: a report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. Eur J Prev Cardiol. 2021;28(4):370\u20139.","journal-title":"Eur J Prev Cardiol"},{"key":"537_CR47","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4103\/ijpvm.IJPVM_365_19","volume":"12","author":"M Maiello","year":"2021","unstructured":"Maiello M, Cecere A, Zito A, et al. Low-dose aspirin for primary prevention of cardiovascular events in postmenopausal women with type-2 diabetes: the prescriptive approach in the real world. Int J Prev Med. 2021;12:140.","journal-title":"Int J Prev Med"},{"key":"537_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100548","volume":"27","author":"R Bugiardini","year":"2020","unstructured":"Bugiardini R, Pavasovi\u0107 S, Yoon J, et al. Aspirin for primary prevention of ST segment elevation myocardial infarction in persons with diabetes and multiple risk factors. EClinicalMedicine. 2020;27: 100548.","journal-title":"EClinicalMedicine."},{"key":"537_CR49","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(21)01827-4","volume":"398","author":"P Joseph","year":"2021","unstructured":"Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398:1133\u201346.","journal-title":"Lancet"},{"key":"537_CR50","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Baigent","year":"2009","unstructured":"Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849\u201360.","journal-title":"Lancet"},{"key":"537_CR51","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.7326\/M21-2596","volume":"174","author":"RB Burns","year":"2021","unstructured":"Burns RB, Pignone M, Michos ED. Would you recommend aspirin to this patient for primary prevention of atherosclerotic cardiovascular disease? Grand rounds discussion from Beth Israel Deaconess Medical Center. Ann Intern Med. 2021;174:1439\u201346.","journal-title":"Ann Intern Med"},{"key":"537_CR52","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.2015.15629","volume":"316","author":"R Chou","year":"2016","unstructured":"Chou R, Dana T, Blazina I, et al. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services task force. JAMA. 2016;316:2008\u201324.","journal-title":"JAMA"},{"key":"537_CR53","doi-asserted-by":"publisher","first-page":"6691","DOI":"10.1038\/s41598-021-86192-4","volume":"11","author":"YJ Oh","year":"2021","unstructured":"Oh YJ, Kim AJ, Ro H, et al. Low-dose aspirin was associated with an increased risk of cardiovascular events in patients with chronic kidney disease patients and low bodyweight: results from KNOW-CKD study. Sci Rep. 2021;11:6691.","journal-title":"Sci Rep"},{"key":"537_CR54","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/bmj.321.7270.1183","volume":"321","author":"S Derry","year":"2000","unstructured":"Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183\u20137.","journal-title":"BMJ"},{"key":"537_CR55","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/j.cgh.2015.05.025","volume":"13","author":"RH Palmer","year":"2015","unstructured":"Palmer RH. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2015;13:2023\u20134.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"537_CR56","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/ebm1304","volume":"16","author":"JM Siller-Matula","year":"2011","unstructured":"Siller-Matula JM, Delle-Karth G. Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding. Evid Based Med. 2011;16:144\u20135.","journal-title":"Evid Based Med"},{"key":"537_CR57","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/8755122519867906","volume":"36","author":"CA Ingram","year":"2020","unstructured":"Ingram CA, Giang G, Mccrory K, et al. Yosprala: coordinated delivery of a proton pump inhibitor and aspirin. J Pharm Technol. 2020;36:78\u201383.","journal-title":"J Pharm Technol"},{"key":"537_CR58","first-page":"11","volume":"17","author":"S Khodayar","year":"2018","unstructured":"Khodayar S, Bardania H, Shojaosadati SA, et al. Optimization and characterization of aspirin encapsulated nano-liposomes. Iran J Pharm Res. 2018;17:11\u201322.","journal-title":"Iran J Pharm Res."},{"key":"537_CR59","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/pharmaceutics14010187","volume":"14","author":"R Mollace","year":"2022","unstructured":"Mollace R, Gliozzi M, Macr\u00ec R. Efficacy and safety of novel aspirin formulations: a randomized, double-blind, placebo-controlled study. Pharmaceutics. 2022;14:187.","journal-title":"Pharmaceutics"},{"key":"537_CR60","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(18)31133-4","volume":"392","author":"PM Rothwell","year":"2018","unstructured":"Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018;392:387\u201399.","journal-title":"Lancet"},{"key":"537_CR61","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1055\/s-0039-1687905","volume":"45","author":"M Christiansen","year":"2019","unstructured":"Christiansen M, Grove EL, Hvas A-M. Primary prevention of cardiovascular events with aspirin: toward more harm than benefit\u2014a systematic review and meta-analysis. Semin Thromb Hemost. 2019;45:478\u201389.","journal-title":"Semin Thromb Hemost"},{"key":"537_CR62","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","volume":"326","author":"DG Altman","year":"2003","unstructured":"Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219.","journal-title":"BMJ"},{"key":"537_CR63","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1056\/NEJMe1906559","volume":"381","author":"D Harrington","year":"2019","unstructured":"Harrington D, D\u2019agostino RB Sr, Gatsonis C, et al. New guidelines for statistical reporting in the journal. N Engl J Med. 2019;381:285\u20136.","journal-title":"N Engl J Med"},{"key":"537_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d2234","volume":"342","author":"S Bangalore","year":"2011","unstructured":"Bangalore S, Kumar S, Wetterslev J, et al. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ. 2011;342: d2234.","journal-title":"BMJ"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00537-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-022-00537-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00537-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T22:13:03Z","timestamp":1727215983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-022-00537-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["537"],"URL":"https:\/\/doi.org\/10.1007\/s40256-022-00537-6","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"11 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this was a systematic review of meta-analyses, no ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors received no support from any organizations for the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mingming Wang, Haijie Yu, Zuojing Li, Daxin Gong, and Xiaoxi Liu have no financial or proprietary interests in any material discussed in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable (meta-analysis).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The authors confirm that the data supporting the findings of this study are available in the article and its online supplementary material.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"MW and HY were engaged in the design of the study, interpretation of the data, statistical analyses, and drafting of the manuscript. ZL and DG were responsible for data extraction, statistical analyses, interpretation of the data, and administrative and technical support. MW and XL were responsible for the conception and critical revision of the manuscript. All authors read and approved the final version of manuscript.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}